2016 Grants & Awards
Grants-in-aid of research RECIPIENTS
Crohn’s and Colitis Canada's Grants-in-Aid of Research program supports Canadian inflammatory bowel disease (IBD) research. The intention of the program is to help advance prevention, treatments, health policy, and to ultimately move us closer to discovering cures for Crohn's disease and ulcerative colitis. These grants support Canadian research projects which have a defined objective and are conducted by an investigator who is either working alone or in collaboration with others. The grants are awarded for up to three years at a maximum of $125,000 per year.
The selection process for the Grants-in-Aid of Research competition is very competitive as each research proposal submitted by either a Canadian researcher or healthcare professional is thoroughly reviewed by a Grant Review Panel comprised of scientific experts and lay persons. The Grant Review Panel scores and ranks the submitted applications based on merit and relevance to the patient community.
Please find below the 2016 recipients of the Grants-in-Aid of Research.
Dr. Laura Targownik | University of Manitoba
Co-investigators: Dr. Eric Benchimol, Dr. Geoff Nguyen, Dr. Lisa Lix, Dr. Sanjay Murthy, Dr. Kevan Jacobson, Dr. Gregory Rosenfeld, Dr. Cynthia Seow, Dr. Gilaad Kaplan, Dr. Jennifer Jones, Dr. Juan Nicholas Pena-Sanchez, Dr. Charles Bernstein, Dr. Harminder Singh, Dr. Alain Bitton, Dr. Maria Vutcovici, and Dr. Murray Krahn
Research: Linking Population Based Provincial Health Care Utilization Databases to Evaluate Drug Related Outcomes in IBD
Dr. Targownik is using provincial health records to see how medications for IBD are being used by Canadians. This work will help healthcare professionals determine whether early use of biologics and/or combination therapy are beneficial to patients.
Dr. Stephen Vanner | Queen’s University
Co-investigators: Dr. Katrina Gee, Dr. David Reed, and Dr. Alan Lomax
Research: Turning off the ‘Switch’: Preserving the Analgesic Actions of the Endogenous Opioid Pathway in IBD
Pain is a debilitating symptom for many with IBD. Dr. Vanner is studying how the abdominal pain seen in IBD is caused and whether there are more effective ways to treat it. Ultimately, this work may lead to better management of pain medications.
Dr. Stuart Turvey | University of British Columbia
Research: Development of Anti-Inflammatory Nanomedicine for Inflammatory Bowel Disease
Dr. Turvey is attaching tiny gold nanoparticles to peptides to reduce inflammation. He’s had positive results so far using this therapy to improve the health IBD mice and will now launch larger scale studies to confirm the benefits. Ultimately, this research will facilitate the development of new nanomedicines to treat people living with IBD.
Dr. Bruce Vallance | University of British Columbia
Co-investigator: Dr. Leigh Knodler
Research: Intestinal Epithelial Inflammasomes: Frontline Defenders against IBD?
Dr. Vallance is studying immune cells involved in protecting gut tissue from foreign bacteria. He is looking at ways of improving these cells’ abilities to control inflammation and promote gut healing in IBD.
Dr. Theodore Steiner | University of British Columbia
Co-investigator: Dr. Megan Levings
Research: Development of Regulatory T cell immunotherapy for IBD
Dr. Steiner is looking to enhance the ability of a white blood cell (regulatory T cells) to keep inflammation in check. They will collect these cells from human volunteers and improve function to find the best method to scale up and develop a therapy for IBD patients.
Dr. Elena Verdu | McMaster University
Research: The role of Microbial Proteases in Colitis
Dr. Verdu will be investigating the impact that bacteria collected from UC patients has on germ-free mice in order to better understand how the certain bacteria may lead to gut leakiness or chronic inflammation seen in IBD.
Dr. Claude Asselin | Université Sherbrooke
Research: Histone deacetylases: epigenetic regulators of intestinal epithelial homeostasis
Our body responds to the environment which can make us more or less susceptible to disease. The environment can cause a gene to turn “on” or “off” through epigenetic changes. Dr. Asselin is studying how certain proteins control genetic and epigenetic information in the gut cells leading to IBD.
INNOVATIONS IN IBD GRANT RECIPIENTS
The Innovations in IBD Grant is a one-year grant, valued at up to $50,000 that funds novel or innovative approaches to IBD research. The grant stimulates and supports research which may not be encompassed within the boundaries of traditional medical research. This award is open to both Canadian and international applicants.
Similar to the Grants-in-Aid of Research, the selection process for the Innovations in IBD Grant competition is very competitive as each research proposal submitted by either a researcher or healthcare professional is thoroughly reviewed by a Grant Review Panel. Comprised of scientific experts and lay persons, the Grant Review Panel scores and ranks the submitted applications based on merit and relevance to the patient community.
Please find below the 2017 recipients of the Innovations in IBD Grant.
Dr. Martin Pelletier | Universite Laval
Research: Characterizing the role of inflammatory cells' bioenergetics in the pathophysiology of colitis
This study aims at characterizing different parameters of energy metabolism in immune cells during disease progression in a mouse model of colitis. This research could enable the development of improved biomarkers for inflammatory bowel disease based on immune cell’s energy metabolism and thus improve the diagnosis or pave the way for new treatments of inflammatory disorders.
Dr. Jane Shearer | University of Calgary
Research: Use of a Mitochondrial Fission Inhibitor as a treatment of Inflammatory Bowel Disease
This innovation grant seeks to understand the relationship between mitochondrial fission, intestinal barrier function and IBD. It will build upon preliminary data showing that targeting mitochondrial fission through a novel peptide inhibitor (P110) may be of therapeutic benefit in IBD. This peptide has been shown to be effective in other disease states where oxidative stress, cell death and fission are implicated.